Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres
Enzyme replacement therapy (ERT) has been shown to stabilize certain aspects of Fabry disease (FD). However, in some patients on ERT, high antibody titres have been documented, with limited clinical improvement in systemic manifestations and often with significant adverse drug reactions. We present...
Main Authors: | Aizeddin A. Mhanni, Christiane Auray-Blais, Michel Boutin, Alie Johnston, Kaye LeMoine, Jill Patterson, Johannes M.F.G. Aerts, Michael L. West, Cheryl Rockman-Greenberg |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-09-01
|
Series: | Molecular Genetics and Metabolism Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214426920300641 |
Similar Items
-
Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients
by: Kazuya Tsuboi, et al.
Published: (2017-06-01) -
Biomarkers in Anderson–Fabry Disease
by: Irene Simonetta, et al.
Published: (2020-10-01) -
Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions
by: Ken Kok, et al.
Published: (2021-02-01) -
Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?
by: Giovanni Duro, et al.
Published: (2018-11-01) -
La malattia di Anderson-Fabry. Conclusioni
by: Giovanni Duro, et al.
Published: (2017-07-01)